Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Amicus Therapeutics, presenting at the Morgan Stanley Global Healthcare Conference, reported strong Q2 sales exceeding $150 million, driven by robust performance of Galafold for Fabry disease and Pombiliti/Opfolda for Pompe disease. The company forecasts significant 2025 growth, projecting 10-15% for Galafold and 50-65% for Pombiliti/Opfolda, underscoring its profitability and growth potential. Additionally, Amicus recently expanded its pipeline by in-licensing a Phase III asset for FSGS, a rare kidney disease.

Analysis

Amicus Therapeutics (NASDAQ:FOLD) presented a strongly positive operational update and forward outlook at the Morgan Stanley Global Healthcare Conference, reinforcing its narrative of achieving both profitability and high growth. The company reported a significant commercial milestone, with Q2 sales surpassing $150 million for the first time, demonstrating robust execution. Growth is driven by two key franchises: the established Galafold therapy for Fabry disease, which is projected to grow 10-15% in 2025, and the newer Pombiliti/Opfolda combination for Pompe disease, which is forecasted to be the primary growth engine with an aggressive 50-65% growth target for 2025. This dual-product momentum is further supplemented by strategic pipeline expansion, evidenced by the recent in-licensing of a Phase III asset for FSGS, a rare kidney disease. This move signals a commitment to long-term growth beyond the current portfolio and aligns with the company's focus on rare diseases.

Key Decisions for Investors

• Investors should closely monitor the quarterly sales trajectory of Pombiliti/Opfolda to validate the company's ability to meet its ambitious 50-65% growth guidance, which is central to the current investment thesis.
• The in-licensing of a late-stage FSGS asset de-risks the future pipeline; tracking upcoming clinical and regulatory milestones for this program is now critical for assessing long-term value creation.
• Given the strong positive guidance and recent performance, it is prudent to assess whether the market has already priced in this optimistic outlook and to consider the execution risk associated with achieving the stated 2025 growth targets.